Stephen Gordon Trans Medics Group, Inc. (TMDX) insider trading activity

Stephen Gordon is Chief Financial Officer of TransMedics Group, Inc.. Currently has a direct ownership of 21,299 shares of TMDX, which is worth approximately $2.95 Million. The most recent transaction as insider was on Jun 03, 2024, when has been sold 2,060 shares (Common Stock) at a price of $135.93 per share, resulting in proceeds of $280,015. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.3K

8.58% 3M change

13.36% 12M change

Total Value Held $2.95 Million

Stephen Gordon Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 03 2024	SELL Open market or private sale	$280,015 $135.93 p/Share	2,060 Reduced 8.82%	21,299 Common Stock
Jun 03 2024	BUY Exercise of conversion of derivative security	$79,227 $38.46 p/Share	2,060 Added 8.1%	23,359 Common Stock
May 29 2024	SELL Open market or private sale	$2,827,600 $141.38 p/Share	20,000 Reduced 48.43%	21,299 Common Stock
May 29 2024	BUY Exercise of conversion of derivative security	$781,560 $43.42 p/Share	18,000 Added 31.41%	39,299 Common Stock
May 06 2024	SELL Open market or private sale	$1,920,000 $128.0 p/Share	15,000 Reduced 39.17%	23,299 Common Stock
May 06 2024	BUY Exercise of conversion of derivative security	$576,900 $38.46 p/Share	15,000 Added 28.14%	38,299 Common Stock
Apr 01 2024	SELL Open market or private sale	$1,110,150 $74.01 p/Share	15,000 Reduced 39.17%	23,299 Common Stock

Apr 01 2024	BUY Exercise of conversion of derivative security	$576,900 $38.46 p/Share	15,000 Added 28.14%	38,299 Common Stock
Mar 08 2024	SELL Open market or private sale	$166,759 $87.63 p/Share	1,903 Reduced 7.55%	23,299 Common Stock
Mar 04 2024	SELL Open market or private sale	$1,242,000 $82.8 p/Share	15,000 Reduced 37.31%	25,202 Common Stock
Mar 04 2024	BUY Exercise of conversion of derivative security	$576,900 $38.46 p/Share	15,000 Added 27.17%	40,202 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	12,127 Added 32.49%	25,202 Common Stock
Feb 01 2024	SELL Open market or private sale	$1,281,750 $85.45 p/Share	15,000 Reduced 53.43%	13,075 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	$339,450 $22.63 p/Share	15,000 Added 34.82%	28,075 Common Stock
Jan 02 2024	SELL Open market or private sale	$1,156,050 $77.07 p/Share	15,000 Reduced 53.43%	13,075 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	$199,200 $13.28 p/Share	15,000 Added 34.82%	28,075 Common Stock
Nov 17 2023	SELL Bona fide gift	-	5,714 Reduced 30.41%	13,075 Common Stock
Oct 02 2023	SELL Open market or private sale	$271,100 $54.22 p/Share	5,000 Reduced 21.02%	18,789 Common Stock
Oct 02 2023	BUY Exercise of conversion of derivative security	$80,700 $16.14 p/Share	5,000 Added 17.37%	23,789 Common Stock
May 01 2023	SELL Open market or private sale	$395,250 $79.05 p/Share	5,000 Reduced 21.02%	18,789 Common Stock
May 01 2023	BUY Exercise of conversion of derivative security	$80,700 $16.14 p/Share	5,000 Added 17.37%	23,789 Common Stock
Mar 01 2023	SELL Open market or private sale	$397,550 $79.51 p/Share	5,000 Reduced 21.02%	18,789 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	$80,700 $16.14 p/Share	5,000 Added 17.37%	23,789 Common Stock
Feb 20 2023	BUY Grant, award, or other acquisition	-	13,075 Added 41.03%	18,789 Common Stock
Feb 01 2023	SELL Open market or private sale	$313,200 $62.64 p/Share	5,000 Reduced 46.67%	5,714 Common Stock

Stephen Gordon

Chief Financial Officer

Andover, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TMDX shares.

Notify only if

Value

Insider Trading

Get notified when an Trans Medics Group, Inc. insider buys or sells TMDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to TransMedics Group, Inc.

Track Activities on TMDX

Account